China’s pharmaceutical stocks surge after state plan targets global biotech leadership by 2030
On September 21, Chinese A-share pharmaceutical and biotech stocks surged, with Novogene, Harbin Pharmaceutical, and others hitting daily trading limits. The rally followed two policy catalysts: a September 18 release of the 15th Five-Year Plan for Pharmaceutical Industry Development, targeting China’s biomedical R&D to rank among the world’s top by 2030, and a September 20 NMPA pledge to prioritize review resources for innovative drugs. The Shanghai Composite rose 0.43%, with the medical sector leading gains.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary awaiting refresh
Summary awaiting refresh
Cross-source coverage
Reporting timeline
China A-Share Market Rises on Drug Policy Support; Analysts See Cautious Outlook
On September 21, China's A-share market saw broad gains, with the Shanghai Composite Index rising 0.97%, the Shenzhen Component Index up 0.65%, and the ChiNext Index gaining 0.8%. Total market turnover reached 2.0481 trillion yuan, slightly down from the previous session, with over 4,500 stocks advancing. The pharmaceutical sector led the rally, particularly innovative drugs and CRO (contract research organization) stocks, following supportive policy announcements. On September 20, the National Medical Products Administration stated that 59 innovative drugs and 51 innovative medical devices have been approved this year, with further support planned. Additionally, a ten-department '15th Five-Year Plan' for the pharmaceutical industry and a new pricing pilot for high-tech medical services were announced. Analysts offered mixed forecasts: Zhongtai Securities sees resources concentrating on innovative drug firms; Guosen Securities expects a gradual, structural rebound amid holiday effects; Galaxy Securities predicts continued volatility; Bank of China International Securities anticipates short-term consolidation with a Q4 rebound; and Huatai Securities notes narrowing opportunities with a neutral tone. The article includes a disclaimer that it does not constitute investment advice.
Read sourceA-Share Rally: 105 Stocks Hit Daily Limit, Drug and Liquor Sectors Surge, Kylin Instrument Drops 5%
On September 21, A-share markets rose with the Shanghai Composite up 0.97%, Shenzhen Component up 0.65%, and ChiNext up 0.8%. Over 4,500 stocks advanced and 105 hit daily trading limits, driven by small-cap and micro-cap stocks. The pharmaceutical sector led gains after China's Ministry of Industry and Information Technology and nine other departments jointly issued the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development' on September 18, calling for AI, quantum computing, and supercomputing to empower drug R&D. The National Medical Products Administration on September 20 also pledged support for large-scale, intensive, and high-end pharmaceutical development. Consumer, tourism, and liquor sectors also rose on pre-holiday positioning. However, high-priced stocks, tech stocks, and institutional favorites underperformed: Kylin Instrument fell over 5%, and the STAR 50 index turned negative intraday. CITIC Securities noted that non-institutional stocks often see new highs after institutional stocks peak in late-stage industrial super-cycles, and recommended AI-related sectors including optical communication, PCB, advanced packaging, wafer manufacturing, and gas turbines. Huatai Securities cautioned that pre-National Day effects and weak economic data limit upside, favoring tech, innovative drugs, and chemicals with dividend stocks as core holdings.
Pharmaceutical Stocks Surge in China on Policy Support and Innovation Drive
On September 21, Chinese pharmaceutical stocks experienced a surge, with multiple sectors including chemical drugs, medical services, and AI-driven pharmaceuticals seeing limit-up moves. Notable stocks such as Harbin Pharmaceutical Group hit the daily limit with over one million buy orders at the top of the order book. The rally followed two key policy events: on September 20, the State Council Information Office held a press conference where National Medical Products Administration Deputy Director Yang Sheng pledged to prioritize review resources to accelerate the market approval of innovative drugs and medical devices that are 'Made in China, New to the World.' On September 18, the Ministry of Industry and Information Technology and nine other departments released the '15th Five-Year Plan for Pharmaceutical Industry Development,' setting a target for China's biomedical R&D and application to rank among the world's top by 2030, with breakthroughs in key core technologies. Analysts at Industrial Securities maintained that 'innovation and internationalization' remain the core theme for the pharmaceutical sector, citing sustained global competitiveness of domestic innovative drugs and unchanged industry logic of policy support, overseas expansion, and commercialization profitability.
Read sourceShow 7 older updatesHide older updates
China A-Share Midday: Shanghai Composite Up 0.55%, Pharma Stocks Surge on Policy Support
On September 21, China's A-share markets opened higher and maintained gains through midday, with the Shanghai Composite rising 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext Index gaining 0.93% to 3403.97. Over 4,300 stocks advanced while more than 1,000 declined, with total half-day turnover across Shanghai, Shenzhen, and Beijing reaching 1.339 trillion yuan, up 10.3 billion from the prior session. The medical and pharmaceutical sector led the rally, driven by two policy catalysts: a September 18 State Council executive meeting that outlined a medical rehabilitation and nursing capacity expansion program, and a September 18 joint release by the Ministry of Industry and Information Technology and other agencies of the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development,' which targets 3.5 trillion yuan in revenue for large-scale pharmaceutical firms by 2030 and a 25% global share for first-in-class new drugs. Sub-sectors including medical services, CRO, innovative drugs, and chemical drugs surged, with multiple stocks hitting daily limits. In contrast, home appliances, precious metals, and insurance sectors declined, as funds rotated out of defensive positions. The report also noted gains in film and PCB sectors, supported by holiday box office expectations and price hikes in electronic-grade glass fiber.
Read sourceBiotech, Pharma, CRO Stocks Surge; Novogene Hits 20% Daily Limit on Policy Boost
On September 21, A-share major indices rose, with the Shanghai Composite up 0.43%, Shenzhen Component up 0.79%, and ChiNext up 1.24%. The biotech, pharmaceutical, and CRO sectors led gains, with Novogene (Novogene) hitting the 20% daily limit up. South China Biological achieved a three-day consecutive limit-up. The rally was attributed to a policy catalyst: on September 18, ten Chinese government departments, led by the Ministry of Industry and Information Technology, jointly issued the 'Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets a target that by 2030, China's biomedical R&D and application will firmly rank among the world's top, with innovation-driven efficiency fully released and key core technologies in key areas achieving systemic breakthroughs. Other gainers included JET Bio-Filtration, Tellgen, and Novoprotein. In contrast, sectors such as home appliances, engineering machinery, and semiconductor equipment declined. Hong Kong markets also rose, with Baidu, Alibaba, and Tencent each gaining over 2%.
Read sourceChina A-shares rise in morning trade; biotech, memory chips surge; Hang Seng Tech reverses gains
On September 21, China's A-share markets opened higher, with the Shanghai Composite up 0.50%, Shenzhen Component up 0.80%, and the ChiNext Index up 1.29% as of writing. The biotech sector led gains, with CRO, innovative drugs, weight-loss drugs, and gene testing concepts surging. Memory chip stocks strengthened, driven by Changxin Technology's 5% rise after announcing its fifth-generation technology platform mass production with over 50% wafer output improvement. Other active sectors included aerospace, defense, catering, tourism, and retail. Hong Kong markets showed divergence: the Hang Seng Index edged up 0.51%, while the Hang Seng Tech Index reversed early gains to turn negative. The Hang Seng Biotech Index surged nearly 5%. In bond markets, treasury futures rose modestly. Commodity futures mostly advanced, with pulp up 3%, while crude oil plunged 6%. The rally was supported by a policy catalyst: on September 18, ten Chinese ministries including MIIT jointly issued the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development,' which promotes AI, quantum computing, and computational medicine in drug R&D.
Read sourceA-Share Midday Review: Shanghai Composite Rises 0.55%, Medical Sector Leads with Surge in Limit-Up Stocks
On September 21, A-share indices opened higher and maintained gains through midday trading, with the Shanghai Composite up 0.55% to 3933.37, the Shenzhen Component up 0.57% to 13718.23, and the ChiNext up 0.93% to 3403.97. Over 4,300 stocks rose, with total half-day turnover reaching 1.339 trillion yuan, up 10.3 billion from the previous session. The medical sector led gains, driven by two policy catalysts: a State Council executive meeting on September 18 announced a medical rehabilitation and nursing capacity expansion project, and on the same day, the Ministry of Industry and Information Technology and nine other departments released the 'Fifteenth Five-Year Plan for Pharmaceutical Industry Development,' targeting 3.5 trillion yuan in revenue and 25% global share of first-in-class drugs by 2030. Medical services, CRO, and innovative drug stocks surged, with multiple stocks hitting daily limits. Capital flows showed net inflows of over 54 billion yuan into the medical sector, while semiconductors, electronics, and electrical equipment saw outflows. Other notable movers included film and PCB stocks, while home appliances and precious metals declined.
Read sourceBiotech, Pharma, CRO Stocks Surge; Novogene Hits 20% Daily Limit on Policy Boost
On September 21, Chinese A-share markets saw a broad uptick, with the Shanghai Composite Index rising 0.43%, the Shenzhen Component Index up 0.79%, and the ChiNext Index gaining 1.24%. The biotechnology, pharmaceutical, and CRO (contract research organization) sectors led gains, with Novogene (Novogene Co., Ltd.) hitting the 20% daily trading limit. Other notable gainers included Nanhua Bio, which rose for a third consecutive day, and JET Bio, Tellgen, and Novoprotein. The rally was attributed to a policy announcement on September 18, when ten government departments including the Ministry of Industry and Information Technology jointly issued the 'Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan sets a target for China to become a world leader in biomedical R&D and application by 2030, with a focus on achieving systemic breakthroughs in key core technologies. Hong Kong markets also rose, with Baidu, Alibaba, and Tencent each gaining over 2%.
Read sourceChina Biotech Stocks Surge; Novogene Hits 20cm Limit-Up on Pharma Plan
On September 21, Chinese A-share major indices rose, with the Shanghai Composite up 0.43%, the Shenzhen Component up 0.79%, the ChiNext up 1.24%, and the Sci-Tech Composite up 0.50% as of press time. The biotechnology, pharmaceutical, and CRO sectors led gains, with Novogene (stock code 688315) hitting a 20cm limit-up. Other gainers included Nanhua Bio, Jet Bio, Tellgen, and J&Y Protein. The rally followed the September 18 release of the '15th Five-Year Plan for Pharmaceutical Industry Development' jointly issued by the Ministry of Industry and Information Technology and nine other departments. The plan sets a target for China's biomedical R&D and application to rank among the world's top by 2030, with full release of innovation-driven efficiency and systematic breakthroughs in key core technologies in critical areas. Hong Kong markets also rose, with Baidu, Alibaba, and Tencent each gaining over 2%.
Read sourcePharmaceutical Stocks Surge in China on Policy Support for Innovation and 15th Five-Year Plan
On September 21, Chinese pharmaceutical and biotech stocks surged, with shares of companies like Novogene, Baihua Pharmaceutical, Aoyang Health, Nanhua Bio, Shenqi Pharmaceutical, Xinhua Pharmaceutical, and Harbin Pharmaceutical (600664) hitting daily trading limits. The rally followed two key policy events. On September 20, the State Council Information Office held a press conference on the 15th Five-Year Plan period for market regulation, where National Medical Products Administration (NMPA) Deputy Director Yang Sheng stated that the agency would concentrate the best review resources to support innovative drugs and medical devices that are 'Made in China, New to the World.' On September 18, the Ministry of Industry and Information Technology and nine other departments released the '15th Five-Year Plan for the Development of the Pharmaceutical Industry,' setting a target for China's biomedical R&D and application to rank among the world's top by 2030, with breakthroughs in key core technologies. Analysts at Industrial Securities noted that the global competitiveness of China's innovative drug sector continues to strengthen, supported by policy backing, overseas expansion, and the realization of commercial profits.
Read source